Muaiad Kittaneh, Head of R and D and Scientific Strategy, shared Syneos Health’s post on LinkedIn, adding:
“The future of oncology drug development is not simply about generating more data. It is about asking better questions, generating meaningful evidence, and making smarter decisions earlier in clinical development.
It was a pleasure joining Ashley Brenton, at BioTechX 2026 in Boston to discuss how artificial intelligence, real – world evidence, and patient insights can help transform clinical development and improve decision – making.
As both an oncologist and a caregiver, it is always an honor to speak about the patient journey from perspectives that extend beyond clinical research. Behind every data point is a patient, a family, and a story that matters.
Ultimately, the patient journey should not simply be an outcome we measure. It should inform every decision we make.
Thank you to Syneos Health for highlighting these important conversations.”
Quoting Syneos Health’s post:
“How can AI, real – world evidence and patient insights improve the decisions that shape clinical development?
At BioTechX 2026 in Boston, Syneos Health experts Muaiad Kittaneh, and Dr. Ashley Brenton, explored how biotech sponsors can use these tools and insights to strengthen trial design, assess feasibility and build a clearer evidence story for physicians and patients.
Read the conference takeaways and their perspectives in this week’s Weekly Sync.”
